CD274 and glioblastoma: Considering the poor effect of immunotherapy in glioblastoma and the absence of ideal biomarkers, the application of this method to predict the effect of immunotherapy may be able to better screen out glioblastoma patients who can benefit from PD‐L1/PD‐L1 blockade, thus allowing the possibility of immunotherapy.